Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Athena's mouse: Modest investment could be a big deal

Athena Neurosciences Inc., which last week announced a transgenic mouse model for Alzheimer's disease, stands to reap a substantial payback from a very modest and quietly executed acquisition of Exemplar Corp.'s work in transgenic disease models.

By overexpressing a mutated human gene for the amyloid precursor

Read the full 463 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE